Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Capricor’s BLA for Deramiocel received Priority Review in March 2025
The company’s largest center for medical device applications, serving the entire Asian market
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Subscribe To Our Newsletter & Stay Updated